52 search results for: expert insights

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

expert video

AD and PN: Commonalities and Differences – A Case Study

10 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

5 min

Dermatology

Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

28 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region